Non-adherence to adjuvant endocrine breast cancer treatment adversely affects disease-free and overall survival. Clinical predictors of non-adherence may allow for specific interventions to reduce non-adherence and improve survival.
Introduction
In Sweden, over 7000 women are diagnosed with breast cancer every year (1).
A majority these women have estrogen receptor (ER) positive tumors (2) . About 70% of women with ER-positive tumors receive adjuvant endocrine treatment (Per Malmström, personal communication, 2011). Hence, every year, 4000-5000 breast cancer patients in Sweden start endocrine treatment.
Adjuvant endocrine treatment significantly prolongs disease-free survival and overall survival for breast cancer patients with hormone receptor positive tumors (3) (4) (5) (6) . Recommended endocrine treatment duration is five years for tamoxifen and two to five years for aromatase inhibitors (AI) (7) . Patients treated with tamoxifen for only one or two years have higher breast cancer mortality than patients who complete five years of tamoxifen therapy (6, 8) .
Non-adherence to adjuvant endocrine treatment has been associated with overall mortality and a shorter disease-free survival in breast cancer patients (9, 10) . Previous publications suggest non-adherence as high as 23.6%
after the first year of follow-up (11, 12) . Non-adherence increases with each consecutive year (11, 12) . Several studies report that non-adherence rates are close to 50% prior to the end of the recommended 5-year treatment period (11-13). Tamoxifen users seem less adherent than AI users (12, 14, 15) , possibly due to differing side-effect profiles (4).
Non-adherence has been associated with both psychological and biological factors. Studies have identified, with often conflicting results, factors associated with poor adherence to breast cancer therapy such as type of breast cancer surgery (16, 17) , severity of side-effects (18, 19) , number of tablets (20) (21) (22) , age (11-13, 15, 20, 23, 24) , depression and/or the use of antidepressants (24, 25) , 
Materials and Methods
Women assessed preoperatively for a primary breast cancer at the Skane University Hospital in Lund, Sweden, were invited to take part in an ongoing prospective study regarding genetic and non-genetic factors that could be associated with breast cancer prognosis. A total of 819 patients were included between October 2002 and June 2010. The patients were invited to participate regardless of age, stage or ethnic background (most women were ethnic Swedes).
Those who had been diagnosed and treated for another type of cancer within the past 10 years were not eligible to participate. We excluded 47 pre-treated patients [interstitial laser thermotherapy (n=11 + one uncertain) or neoadjuvant systemic therapy (n=34 + one patient who received treatment for another cancer between the primary surgery and re-operation). Patients with a follow-up shorter than 1 year were excluded as well, leaving 629 patients. After excluding patients with ERnegative tumors and patients who had not been advised to use adjuvant endocrine therapy, the cohort consisted of 417 patients, figure 1. The study was approved by the Ethics Committee of Lund University (LU75-02).
Written informed consent was collected during the preoperative visit at specify their food intake on the day they filled out the questionnaire. The number of tablets taken for co-morbidities was obtained from the preoperative questionnaire, excluding both vitamins and natural remedies or complementary alternative medications (CAMs). Anatomic Therapeutic Chemical classification system (ATC) codes were used to categorize medications; N06A for antidepressants, N06A-N06C and N05A-N05C for psychiatric medications (no patient used medications from the N05D category), A10 for antidiabetic medications, and C01-C10 for heart medications. Use of heart medications, antidiabetic medications, antidepressants, psychiatric medications and CAMs were coded as dummy variables based on the information obtained from the preoperative questionnaire. CAMs were classified and included according to a previous publication (31) . One person was excluded from both the CAM variable and the concomitant medications variable as we could not identify the reported medication. The preoperative visit usually took place a few days prior to surgery.
Non-adherence to endocrine treatment was assessed at the 1-year and the 2-year follow-up visits. Patients were considered non-adherent if they had declined recommended endocrine therapy, were no longer taking an endocrine therapy upon follow-up, or had taken a pause in endocrine therapy exceeding 20% of the treatment period (32) . Patients who switched from one endocrine therapy to another and did not take a pause in therapy exceeding 20% of the treatment period were considered adherent, based on a previous publication reporting survival benefits for both prematurely switched patients and guideline switched patients (33) . Adherence information was taken from patient charts, follow-up questionnaires, as well as the clinical follow-up form filled in by the research nurse. The clinical follow-up forms recorded the durations of pauses in treatment since the last visit; this information was not always present in the patients' charts.
The age cut-offs examined in relation to adherence were chosen in concordance with earlier publications (11, 13, 15, 23, 24) . A BMI cut-off at 25 kg/m² was used according to WHOs classifications of overweight (34). Central obesity was considered to be present if the WHR was above 0.85 (34). Alcohol consumption was divided into five categories (never, not more than once a month, 2-3 times every month, 2-3 times every week, 4 or more times a week). Current smokers included both daily smokers and party smokers. The two out of three risk factor profile was based on the strongest factors for non-adherence in the single variable analyses. As low histological grade was strongly associated with nonadherence in the single variable analysis, it was added to the two out of four risk factor profile as well. 
Characteristics of the non-adherent patients
At the 1-year follow-up visit, 36 patients out of 417 (8.6%) were non-adherent to their endocrine treatment. Among these non-adherent patients, 13 never commenced endocrine therapy despite being advised to do so, three patients had less than 80% adherence due to pauses in treatment before the 1-year visit, and 20 patients stopped prematurely. At the 2-year follow-up visit, 33 patients out of 339 (9.7%) were non-adherent. Three patients that were non-adherent at the 1-year visit were considered adherent at the 2-year visit. Seven patients had discontinued treatment between the 1-year and 2-year visits, and 26 patients remained non-adherent since the 1-year visit, figure 1.
Adherence in relation to tamoxifen and aromatase inhibitor use
At the 1-year visit, 13 out of the 295 patients (4.4%) treated with tamoxifen but not AI were non-adherent compared with two non-adherent patients out of 77 (2.6%) who had been treated with AI but not tamoxifen. The highest non-adherence was found in the group of prematurely switched patients, eight out of 29 (27.6%) were At the 2-year visit, 17 out of the 222 patients (7.7%) treated with tamoxifen but not AI were non-adherent compared with two non-adherent patients out of 54 (3.7%) who had been treated with AI but not tamoxifen. In the group of prematurely switched patients, four out of 53 (7.5%) were non-adherent. Ten patients declined treatment despite being recommended endocrine therapy and were not included in this analysis.
Adherence in relation to preoperative patient characteristics
Adherence in relation to preoperative patient characteristics is shown in table 2. 
Exogenous hormone use in adherent and non-adherent patients during follow-up
No data regarding side effects from treatment were routinely collected as part of the present study. However, at the 1-year follow-up, 11 (2.9%) of the adherent patients reported current use of either a local estradiol (n=9), systemic combined estradiol and progestin (n=1), or a progestin intrauterine device (n=1). Three 
medroxyprogesterone injections (n=1). At the 2-year visit eight (2.6%) of the adherent patients reported current use of either local estradiol (n=7) or systemic combined estradiol and progestin (n=1), while one (3%) non-adherent patient reported using a local estradiol.
Clinical profiles predicting non-adherence
Two clinical profiles predicted non-adherence at the 1-year and the 2-year follow- 
Disease-free survival in relation to adherence
The 417 patients had a median disease-free survival of 3.02 years (IQR=2.01-4.98). In a multivariate Cox regression model, non-adherence at the 1-year visit was significantly associated with an increased risk for early breast cancer events (HR=2.97, 95% CI 1.08-8.15; P=0.034), adjusted for age and tumor characteristics. Non-adherence at the 2-year visit showed a similar risk (adjusted HR=2.42, 95% CI 0.75-7.80; P=0.14), but was no longer statistically significantly associated with an increased risk of early events.
Discussion
This study identified two clinical profiles associated with a 4-5 fold increased relative risk for non-adherence to adjuvant endocrine breast cancer therapy at the 1-year and 2-year follow-up visits. The profiles consisted in combinations of readily accessible clinical information, namely BMI<25kg/m 2 , preoperative current smoking, alcohol intake less often than twice a month, and low histological grade.
The profiles identified the majority of non-adherent patients (sensitivity ranging from 60.6% to 72.7%) and the majority of adherent patients (specificity ranging from 68.0% to 78.4%). To our knowledge, no single marker has been shown to have similar accuracy in predicting non-adherence.
The present study found that preoperative BMI <25 kg/m 2 , pre- However, previous studies of risk factors for non-adherence have shown contradictory results, which may reflect a true heterogeneity of the non-adherent group of patients. An alternative explanation is that this study, based on a cohort of 417 patients, lacked sufficient statistical power to detect certain associations between risk factors and non-adherence.
Alcohol intake of less than twice a month was not significantly associated with non-adherence in itself, but it strengthened the association between BMI, smoking and non-adherence when combined in the clinical profiles.
This phenomenon may reflect a synergistic effect between risk factors. A lower than average alcohol consumption and smoking are associated with low socioeconomic status (37, 38) and it is possible that the clinical profiles reflect an association between non-adherence and low socioeconomic status. Previous studies suggest that alcohol abstainers are more likely to be on psychotropic drugs (38) , which may indicate a psychological background to the increased nonadherence. In the present study, no significant associations between alcohol consumption and antidepressant use or psychiatric medication use were found (data not shown). Another study found that smokers were more likely to be non- While a low BMI is associated with a high socioeconomic status in the western world (37, 39) , its inclusion in the clinical profiles increased the profiles' predictive accuracy. A recent study reported that breast cancer patients with a higher BMI were more persistent in taking their endocrine therapy than patients with a lower BMI, which is in line with our finding (40) .
Smoking, BMI and alcohol intake have been associated with estrogen levels in previous studies. Smoking has been reported to have anti-estrogenic effects (41, 42) . A high BMI in women correlates with increased levels of estrogen, compared with lower BMIs (43) . The association between alcohol intake and estrogen levels is unclear. Alcohol may increase estrogen levels, resulting in lower levels among abstainers and seldom-drinkers (44) . However, a pilot study of 59 patients in this cohort suggested that alcohol confers a weaker estrogen metabolite profile (45) . As estrogen levels are closely related to hot flashes and other vasomotor symptoms (46) , and vasomotor symptoms are commonly reported side effects of endocrine treatment (4), a biochemical basis may account for the increased non-adherence in patients identified by the risk factor profiles.
Data regarding side-effects were not routinely collected as part of this study.
However, a few patients, both adherent and non-adherent reported use of exogenous hormones at the follow-up visits, possibly to relieve side-effects. 
adherence among patients who anticipate less therapeutic gain from endocrine treatment (29) . It is also possible that the treating physicians advocate adjuvant therapy more aggressively when the histological grade is high than when it is low.
The present study had a higher percentage of adherent patients at the 1-year and 2-year follow-up visits compared to previous publications (11, 13). The study population included 50% of the breast cancer patients in Lund and were similar, with regards to age, ER-and PR-status, to the 50% of breast cancer patients in Lund who were not included. However, the 417 patients in the present study returned to the hospital for study follow-up visits several times during the 2-year follow-up. During these visits they had personal contact with a research nurse. This increased contact with health care personnel may have resulted in higher rates of adherence. This was a single center study in a Sweden and we do not know how generalizable the results are to other institutions. To our knowledge, there are no published papers regarding clinical profiles in relation to endocrine adherence in breast cancer patients.
Adherence may be measured in several ways, with varying advantages and disadvantages (32) . Most methods, including the use of questionnaires, are susceptible to patient self-presentational bias (32) .
Measurements of medication, estrogen or metabolite blood levels were not performed in this study. Questions regarding medication use, including endocrine treatment, referred to use during the past week, thus minimizing the risk for recall bias. However, we do not know what medications were actually taken between visits. One patient wrote on her questionnaire that she chose to only take her medications every other day (she was considered non-adherent). It is possible that the population included similar cases and that the actual rate of non-adherence is 
higher than measured in the present study. When absolute treatment durations and switch dates could not be obtained in the questionnaire, the clinical follow-up form, patient charts and pathology reports were consulted. In addition, the research nurses recorded pauses, which were not always recorded in the patient charts. Any underreporting would bias the results towards the null. Although other methods of assessing adherence may generate cohorts with larger numbers of patients, gathering information from questionnaires, pathology reports, and patient charts minimizes inaccuracies.
Many previous publications have assessed non-adherence based on prescription records (9, 10, 12) . While it is not certain that the patients who collect their prescriptions take their medicine as prescribed, prescription-based studies may fail to include patients who refuse to start endocrine treatment and who are not issued a prescription in the first place. This study identified 13 non-adherent patients, constituting 36.1% of the non-adherent subgroup, who never commenced recommended endocrine treatment.
Non-adherence was not assessed beyond the 2-year visit due to the smaller number of patients included in the later follow-up visits. Only current smoking status was available in the questionnaires. Hence, former smokers were included in the group of non-smokers, which may have biased the analyses.
Similarly, only current alcohol consumption was recorded at the preoperative questionnaire. Therefore, the category of abstainers may include both former drinkers and life-long abstainers.
In the current study, non-adherence at the 1-year follow-up visit was associated with a nearly 3-fold increase in the risk of early breast cancer events.
Non-adherence impacts negatively on patient survival (5, 6) . In order to justify targeted interventions, screening tests should demonstrate both adequate sensitivity and specificity (47) . The two clinical profiles demonstrated a sensitivity for non-adherence ranging from 60.6% to 72.7% and a specificity ranging from 68.0% to 78.4%.
As reviewed by Hadji (48) to biannual screening for patients < age 40 or > age 72 years (50) . The clinical implication of this change in follow-up warrants close observation.
In conclusion, this study identified two clinical profiles strongly associated with non-adherence to adjuvant endocrine breast cancer therapy at both the 1-year and the 2-year follow-up visits. Given that non-adherence impacts negatively on survival (5, 6) , that the profiles are derived from readily available clinical information, and that targeted interventions to decrease non-adherence are harmless and cheap, these profiles may benefit patient care if they can be validated in independent patient populations. 
